Digital render of Novo Nordisk's manufacturing expansion in Clayton, NC (Credit: Novo Nordisk)
June 24, 2024 02:15 PM EDTUpdated 06:08 PM
Manufacturing

No­vo Nordisk bud­gets $4.1B for new US man­u­fac­tur­ing site as it aban­dons plans for Irish build

Anna Brown

News Reporter

No­vo Nordisk is fur­ther boost­ing man­u­fac­tur­ing in the US for its obe­si­ty drugs as it in­jects $4.1 bil­lion for a sec­ond fill-fin­ish fa­cil­i­ty in Clay­ton …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Af­ter lack­lus­ter 2024, bio­phar­ma in­dus­try prays stalled M&A will fi­nal­ly move in­to gear

Coave rais­es €32M Se­ries A de­spite be­ing two years away from the clin­ic

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

A service from the Financial Times